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guide wires. However, the development of guide wires suited for
interventional MRI is warranted.
Preoperatively, MRI allowed noninvasive assessment of cardiovas-
cular anatomy and function. During and after implantation, the
position of the prosthetic valve was easy to determine. Besides this
morphologic information, MRI provided immediate post-
intervention physiologic parameters of cardiac function and perfusion
of the proximal course of the coronary arteries. In addition, VEC
MRI demonstrated optimal function of the implanted prosthetic valve
in five cases and mild central valvular insufficiency in two cases.
In conclusion, the results of this study imply that MRI is a
promising tool for transcatheter placement of valved stents. How-
ever, further validation of safety aspects is needed in chronic
studies with larger numbers of animals.
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Feasibility of Adjusting Paced Left Ventricular Activation
by Manipulating Stimulus Strength
To the Editor: Cardiac resynchronization therapy (CRT) im-
proves symptoms and decreases hospitalizations in selected pa-
tients with heart failure (1,2). With CRT, pacing from the left
ventricle (LV) alters the ventricular activation (VA) sequence,
changing the QRS morphology. In responders, change in VA
improves cardiac filling and ejection (3). However, many patients
are nonresponders. The LV lead location is the major determinant
of paced activation but is often constrained by the location of
coronary sinus vein branches. During LV mapping for ventricular
tachycardia, increased pacing stimulus strength (SS) has been
demonstrated to capture an enlarged myocardial area, producing a
larger “virtual electrode” (4). If the enlarged area of myocardial
capture extends beyond a discrete region of conduction block, the
SS increase could result in VA change and more rapid conduction
to a remote location, such as the right ventricular (RV) apex.
We hypothesized that paced VA can be manipulated by
increasing SS. We expected activation changes to be more marked
when pacing near areas of scarred or infarcted myocardium.
Ten patients with New York Heart Association functional class
II and III congestive heart failure, ejection fraction40%, referred
for ablation were enrolled according to protocols approved by the
Brigham and Women’s Hospital human subject protection com-
mittee.
Using an electroanatomic mapping system (CARTO, Biosense-
Webster Inc., Diamond Bar, California), three-dimensional plots
(mean of 136  47 points per patient) of bipolar electrogram
amplitude were created (5). Endocardial LV mapping was per-
formed with a 7-F steerable catheter (Biosense-Webster Inc.).
Electrograms were recorded on a separate digital system (Prucka
Engineering Inc., Houston, Texas). Epicardial mapping by percu-
taneous subxiphoid approach was performed in one patient.
Catheter stability was confirmed by biplane fluoroscopy, the
mapping system, and continuous monitoring of electrogram mor-
phology and timing.
Pacing at outputs of threshold, 5 mA, and 10 mA was
performed at 6 to 10 separated LV sites. In one case, epicardial
pacing at 20 mA was performed because of high pacing threshold
(10 mA). The anode was in the inferior vena cava (IVC). A
quadripolar catheter at the RV apex was the reference catheter.
Atrial, ventricular, and His bundle electrograms were assessed to
exclude antegrade atrial conduction during pacing.
Stimulus to RV conduction times and stimulus to QRS con-
duction times (QRS latency) were measured from the stimulus
artifact to the first bipolar peak of the electrogram from the RV
apical catheter and to the earliest VA in the surface electrocardio-
gram (ECG). Changes in QRS morphology with pacing were
defined as any of the following: QRS width change of 40 ms;
new Q-, R-, or S-wave of 25% of the total QRS amplitude;
50% change in ratio of R or S components of QRS complex;
Table 1. Parameters With Stimulus Strength Alteration
Total
Unchanged
QRS
Changed
QRS p Value†
Pacing sites 95 78 17
Stim to RV (ms)
Threshold 118  62* 111 52* 150 93 0.0001
10 mA 95  43 96  43 87  44
QRS duration (ms)
Threshold 199  39* 196 40‡ 213  28‡ 0.03
10 mA 192  43 191  37 195  31
QRS latency (ms)
Threshold 47  52* 36 39‡ 99  73‡ 0.0001
10 mA 32  34 27  29 54  49
Electrogram amplitude
(mV)
2.0  2.0 2.3 2.1 0.8  1.1 0.007
*p  0.001 for comparison of threshold with 10 mA stimulus strengths. †p value
reported for changed versus unchanged QRS. ‡p  0.05 for threshold versus 10 mA
stimulus strengths.
RV  right ventricle.
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precordial transition change of more than one lead;30° change in
QRS axis (6).
Ventricular activation indices were analyzed at threshold and at
10 mA of current output. Comparisons of continuous, paired data
were made using paired t tests. Where appropriate, results were
adjusted using repeated measures analysis of variance to account
for multiple observations in individual patients. A p value of0.05
was considered significant. Analysis was conducted using SAS
software (Version 8.2, SAS Institute Inc., Cary, North Carolina).
Electroanatomic LV endocardial voltage maps were analyzed in
10 patients with ventricular dysfunction. One patient had an
additional epicardial map. The mean ejection fraction was 25 
9%, mean QRS duration was 151  37 ms, and 80% had coronary
artery disease.
Pacing was performed at 95 LV sites (Table 1). Increasing SS
from threshold (3.31  1.5 mA) to 10 mA reduced QRS latency
(47 52 ms to 32 34 ms; p 0.001) and conduction time from
LV pacing site to RV apex (118  62 ms to 95  43 ms; p 
0.0001).
At 17 of 95 (18%) LV sites in 6 of 10 patients, a significant
change in paced QRS morphology was observed. The QRS
morphology changes (Fig. 1) were associated with decreases in
Figure 1. (A) Endocardial bipolar electroanatomic map of the left ventricle (LV). Normal voltage areas are purple, and electrogram amplitude progressively
diminishes as colors proceed to blue, green, yellow, and red. Unexcitable scar with pacing threshold 10 mA is gray (4). There is a large anteroapical scar
(gray). The yellow arrow and dot indicate the site of pacing near the apex. (B) Paced 12-lead electrocardiograms during threshold (left) and 10 mA
high-output pacing (right) at the site indicated in panel A. The initial R-wave in V3 and V4 increases with high output pacing. (C) Corresponding
intracardiac signals from the right ventricle apex (RVA) and five electrocardiogram (ECG) leads. Threshold pacing is shown on the left; high-output pacing,
on the right. The stimulus to RVA electrogram time shortens from 275 to 199 ms with increase in stimulus strength. (D) Epicardial bipolar electroanatomic
map of the LV. The yellow arrow and dot indicate the pacing site at the basal free wall of the LV, between two small areas of unexcitable scar (gray).
Continued on next page.
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conduction time to the RV (62  76 ms vs. 14  25 ms at sites
with changes; p  0.0001), QRS latency (45  41 ms vs. 9  26
ms; p  0.0001), and QRS duration (18  22 ms vs. 4  19 ms;
p  0.03). All ventricles had abnormal low amplitude (1.5 mV)
areas. Pacing sites exhibiting QRS morphology changes with
increasing SS had a lower mean electrogram amplitude of 0.8 
1.1 mV, compared with sites where SS did not influence QRS
morphology (2.3  2.1 mV; p  0.007).
Surface QRS morphology changes identified pacing sites where
VA parameters can be significantly altered with increasing SS,
likely reflecting the proximity of pacing sites to discrete areas of
conduction block, a more probable scenario in low-voltage areas.
Increasing SS during LV pacing reduces conduction time from
the LV to the RV and can produce a sufficient change in VA to
produce a change in QRS morphology. These findings are consis-
tent with an increase in virtual electrode size as SS is increased.
The effect appears most marked in low-amplitude regions, such as
infarct borders (5). Although QRS duration and magnitude of
reduction in QRS duration may not reliably correlate with re-
sponse to CRT (7), VA change is necessary for successful resyn-
chronization. Anatomic constraints in lead position may result in
failure to respond to CRT (3). Our findings indicate that SS can
be manipulated to influence VA. Potentially, resultant changes in
QRS latency and morphology could be used to influence paced
interventricular and intraventricular delays during CRT.
Potential limitations of application to CRT include phrenic
nerve capture at high SS and shortened device battery life. Study
limitations include a small patient number and a potential selection
bias of electroanatomic mapping points during ablation. Pacing
was endocardial in all but one patient, but epicardial pacing in one
patient demonstrated similar VA parameter decreases with QRS
morphology changes at three of eight pacing sites. We used
unipolar pacing with an anode in the IVC to eliminate the
confounding effects of anodal capture, whereas the anode in CRT
devices is at the ring of the RV apical lead. The impact of SS when
using current CRT systems requires further investigation with
hemodynamic correlation.
Increases in SS can change paced VA. The changes can be
marked and are more likely to occur in abnormal areas associated
with scar or infarction that are marked by low electrogram voltage.
Manipulation of the virtual electrode by altering SS may provide a
simple means of adjusting CRT.
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Figure 1 Continued. (E) 12-lead ECGs during pacing at threshold (left) and 20 mA high-output pacing (right) at the site shown in panel A. In leads V3
through V6, an increase in R-wave occurs with high-output pacing. (F) Intracardiac signal from the RVA and five ECG leads. Threshold pacing is shown
on the left; high output pacing, on the right. The stimulus to RVA electrogram time shortens from 392 to 208 ms with increase in stimulus strength.
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Torasemide Inhibits Transcardiac Extraction of Aldosterone in Patients
With Congestive Heart Failure
To the Editor: Loop diuretics such as furosemide and torasemide
are important for the symptomatic treatment of congestive heart
failure (CHF). Recently, in the TOrasemide In Congestive Heart
Failure (TORIC) study, torasemide had a more beneficial effect on
the mortality and morbidity of patients with CHF than furosemide
(1). The mechanism by which torasemide provides a greater
benefit than furosemide remains unknown, but experimental
studies indicate that torasemide may inhibit the binding of
aldosterone (ALD) to its receptor in the cytoplastic fraction of the
rat kidney (2,3). Therefore, in the present study, we evaluated the
transcardiac extraction of ALD, as a potential marker of ALD
action in the heart (4,5), in torasemide therapy compared with
furosemide therapy in the treatment of patients with CHF.
The subjects were 60 consecutive patients with CHF (left
ventricular ejection fraction 45%). Patients receiving spironolac-
tone were excluded. Informed consent was obtained from all
patients before participation in the study, and the protocol was
approved by the Human Investigations Committee of our institu-
tion. Sixty patients were divided randomly into two groups that
were treated with either furosemide (n  30) or torasemide (n 
30) for one month. In the furosemide group, the same dose of
furosemide was continued. In the torasemide group, furosemide
was changed to torasemide at a dose with comparable diuretic
efficacy (furosemide 40 mg/day changed to torasemide 8 mg/day).
After one month, blood samples for measuring plasma ALD
were collected simultaneously from the aortic root (AO) and
coronary sinus (CS), and measurements of neurohumoral factors
were performed as previously reported (4,5).
All results are expressed as mean values  SEM. Univariate
analyses were performed using the Student t test. Linear regression
analysis was used to determine the relationship between continu-
ous variables. A p value  0.05 was regarded as significant.
There was no difference in patient characteristics between the
two groups (Table 1). In the torasemide group, the mean dose of
torasemide was 10.1  0.7 mg/day (range, 4 to 16 mg/day).
One month after randomization, there were no differences in
hemodynamic parameters. In the furosemide group, the plasma ALD
level in the CS was significantly lower than that in the AO (73.1 
10.0 pg/ml vs. 56.9  6.5 pg/ml; p  0.001). In contrast, there was
no difference in plasma ALD levels between the AO and the CS in
the torasemide group (85.4 10.5 pg/ml vs. 83.1 11.6 pg/ml) (Fig.
1). Plasma procollagen type III aminoterminal peptide in the CS
concentration was significantly lower in the torasemide group than
that in the furosemide group (0.52  0.03 U/ml vs. 0.67  0.06
U/ml; p 0.05). There was a significant negative correlation between
the dose of torasemide and the transcardiac gradient (AO–CS) of
ALD in the torasemide group (r  0.56, p  0.01).
We evaluated the transcardiac extraction of ALD as a potential
marker of ALD action in the heart (4,5) in patients with CHF. In
the furosemide group, the plasma ALD level in the CS was
significantly lower than that in the AO. In contrast, there was no
difference in plasma ALD level between the AO and the CS in the
torasemide group. The transcardiac gradient (AO–CS) of ALD
and the extraction ratio of ALD in the AO were significantly lower
in the torasemide group than those in the furosemide group.
Plasma procollagen type III aminoterminal peptide concentration,
a biochemical marker of fibrosis, was significantly lower in the
torasemide group than in the furosemide group. These findings
may indicate that unlike furosemide, torasemide has an ALD
receptor antagonist in the heart. Experimental studies indicate that
torasemide inhibits the binding of ALD to its receptor in the
cytoplastic fraction of rat kidney (2,3). Moreover, the serum
potassium level was significantly higher in the torasemide group
than in the furosemide group in a large series (i.e., TORIC study).
Table 1. Clinical Characteristics of Patients in the Furosemide and Torasemide Groups at
Randomization
Furosemide
(n  30)
Torasemide
(n  30) p Value
Age (yrs) 63.7  1.8 61.5  2.5 NS
Gender (male/female) 23/7 22/8 NS
Etiology of left ventricular dysfunction
Dilated cardiomyopathy 19 15 NS
Ischemic cardiomyopathy 11 15 NS
NYHA functional class
II 17 16 NS
III to IV 13 14 NS
Left ventricular ejection fraction by echocardiography (%) 34.9  1.7 33.5  1.6 NS
Treatment
Dose of furosemide (mg) 46.7  3.1 50.7  3.5 NS
Digitalis 19 15 NS
ACE inhibitors or ARB 21 22 NS
Beta-blockers 13 14 NS
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; NS  not significant; NYHA  New York
Heart Association.
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